Price · as of 2024-12-31
—
Market cap 193.71M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $76.00 | — |
| Intrinsic Value(DCF) | $2.43 | — |
| Graham-Dodd Method(GD) | $1.80 | — |
| Graham Formula(GF) | $4.80 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $23.60 | |||
| 2011 | $0.00 | $24.10 | |||
| 2012 | $0.00 | $8.20 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $5.60 | |||
| 2015 | $0.00 | $45.70 | |||
| 2016 | $0.00 | $53.90 | |||
| 2017 | $0.00 | $105.10 | |||
| 2018 | $0.00 | $94.50 | |||
| 2019 | $15.62 | $7,986.78 | $0.65 | $0.00 | $0.00 |
| 2020 | $4.85 | $30.19 | $0.00 | $0.00 | $259.80 |
| 2021 | $3.67 | $2,026.05 | $7,724.54 | $11.90 | $17,460.30 |
| 2022 | $4.32 | $68.80 | $1.47 | $0.00 | $35.40 |
| 2023 | $3.62 | $33.92 | $21.24 | $0.00 | $0.00 |
| 2024 | $3.65 | $64.98 | $1,485.47 | $1.80 | $4.80 |
AI valuation
Our deep-learning model estimates Genfit S.A.'s (GNFT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $76.00
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.43
— upside
Graham-Dodd
$1.80
— upside
Graham Formula
$4.80
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GNFT | Genfit S.A. | $3.89 | 193.71M | +1,570% | -38% | -54% | +23% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| EPRX | Eupraxia Pharmaceuticals … | $5.67 | 203.77M | — | — | — | — | -5.48 | 4.23 | — | -3.01 | — | 4.23 | 0.00% | — | — | -144.55% | 1233.17% | -93.26% | 0.00 | -44.74 | 11.10 | 10.74 | 0.92 | -3504.00% | — | 4455.00% | -21.32% | -9.67 | 955.80% | 0.00% | 0.00% | 17.10% | -2.78 | -3.59 | — | 19.45 |
| IVA | Inventiva S.A. | $4.10 | 213.13M | +611% | -70% | — | +3,663% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| IVVD | Invivyd, Inc. | $1.52 | 182.32M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| MDWD | MediWound Ltd. | $18.15 | 197.42M | +13% | -60% | — | — | -5.58 | 5.41 | 8.34 | -4.71 | -1.84 | 5.43 | 8.81% | -95.85% | -149.46% | -96.33% | 446.97% | -43.19% | 0.22 | -34.55 | 1.97 | 1.85 | 0.08 | 30400.00% | 822.00% | 1753.00% | -11.80% | -0.51 | 458.83% | 0.00% | 0.00% | 0.00% | -6.83 | -6.65 | 6.55 | -1.69 |
| NTHI | NEONC TECHNOLOGIES HOLDIN… | $11.01 | 212.26M | — | — | — | — | — | — | — | — | — | — | 100.00% | -8605.45% | -14335.50% | 122.08% | 110.23% | -508.20% | 0.00 | -2.64 | 0.25 | 0.02 | 0.00 | -2125.00% | 1779.00% | 12414.00% | — | -0.47 | 65.03% | — | 0.00% | — | — | — | — | — |
| OBIO | Orchestra BioMed Holdings… | $3.92 | 211.5M | +476% | -57% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
| PRLD | Prelude Therapeutics Inco… | $1.39 | 105.76M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| SLS | SELLAS Life Sciences Grou… | $1.68 | 177.08M | — | — | — | — | -2.36 | 7.69 | — | 94.85 | — | 9.65 | 0.00% | — | — | -4147.88% | 484.07% | -240.78% | 0.11 | — | 1.72 | 1.46 | -20.39 | -6269.00% | — | -409.00% | -48.61% | -3.72 | 543.81% | 0.00% | 0.00% | 15.46% | -1.90 | -1.69 | — | -18.42 |
| TARA | Protara Therapeutics, Inc… | $4.44 | 171.3M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
About Genfit S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
- CEO
- M. Pascal Prigent
- Employees
- 180
- Beta
- 0.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.43 ÷ —) − 1 = — (DCF, example).